These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30593627)

  • 1. Studying the Hepatitis C Virus-Induced Epigenetic Signature After Cure with Direct-Acting Antivirals.
    Perez S; Gal-Tanamy M
    Methods Mol Biol; 2019; 1911():191-207. PubMed ID: 30593627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
    Perez S; Kaspi A; Domovitz T; Davidovich A; Lavi-Itzkovitz A; Meirson T; Alison Holmes J; Dai CY; Huang CF; Chung RT; Nimer A; El-Osta A; Yaari G; Stemmer SM; Yu ML; Haviv I; Gal-Tanamy M
    PLoS Genet; 2019 Jun; 15(6):e1008181. PubMed ID: 31216276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
    Hamdane N; Jühling F; Crouchet E; El Saghire H; Thumann C; Oudot MA; Bandiera S; Saviano A; Ponsolles C; Roca Suarez AA; Li S; Fujiwara N; Ono A; Davidson I; Bardeesy N; Schmidl C; Bock C; Schuster C; Lupberger J; Habersetzer F; Doffoël M; Piardi T; Sommacale D; Imamura M; Uchida T; Ohdan H; Aikata H; Chayama K; Boldanova T; Pessaux P; Fuchs BC; Hoshida Y; Zeisel MB; Duong FHT; Baumert TF
    Gastroenterology; 2019 Jun; 156(8):2313-2329.e7. PubMed ID: 30836093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus.
    Takeda H; Takai A; Iguchi E; Mishima M; Arasawa S; Kumagai K; Eso Y; Shimizu T; Takahashi K; Ueda Y; Taura K; Hatano E; Iijima H; Aoyagi H; Aizaki H; Marusawa H; Wakita T; Seno H
    Carcinogenesis; 2021 May; 42(5):672-684. PubMed ID: 33617626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
    Ioannou GN; Feld JJ
    Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.
    Virzì A; Roca Suarez AA; Baumert TF; Lupberger J
    Cold Spring Harb Perspect Med; 2020 Jan; 10(1):. PubMed ID: 31501266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients.
    Cucchetti A; D'Amico G; Trevisani F; Morelli MC; Vitale A; Pinna AD; Cescon M;
    Dig Liver Dis; 2018 Feb; 50(2):156-162. PubMed ID: 29102521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation.
    Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Ohnami S; Nagashima T; Hatakeyama K; Kakuda Y; Sugino T; Urakami K; Akiyama Y; Yamaguchi K
    Cancer Med; 2022 Apr; 11(8):1769-1786. PubMed ID: 35174643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
    Beste LA; Green PK; Berry K; Kogut MJ; Allison SK; Ioannou GN
    J Hepatol; 2017 Jul; 67(1):32-39. PubMed ID: 28267622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.
    Kanda T; Lau GKK; Wei L; Moriyama M; Yu ML; Chuang WL; Ibrahim A; Lesmana CRA; Sollano J; Kumar M; Jindal A; Sharma BC; Hamid SS; Kadir Dokmeci A; Mamun-Al-Mahtab ; McCaughan GW; Wasim J; Crawford DHG; Kao JH; Ooka Y; Yokosuka O; Sarin SK; Omata M
    Hepatol Int; 2019 Nov; 13(6):649-661. PubMed ID: 31541423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.
    Ooka Y; Miho K; Shuntaro O; Nakamura M; Ogasawara S; Suzuki E; Yasui S; Chiba T; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N; Mochizuki H; Omata M
    Hepatol Int; 2018 Nov; 12(6):523-530. PubMed ID: 30242733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma.
    Vescovo T; Refolo G; Vitagliano G; Fimia GM; Piacentini M
    Clin Microbiol Infect; 2016 Oct; 22(10):853-861. PubMed ID: 27476823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reverse inflammaging: Long-term effects of HCV cure on biological age.
    Oltmanns C; Liu Z; Mischke J; Tauwaldt J; Mekonnen YA; Urbanek-Quaing M; Debarry J; Maasoumy B; Wedemeyer H; Kraft ARM; Xu CJ; Cornberg M
    J Hepatol; 2023 Jan; 78(1):90-98. PubMed ID: 36152762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.
    He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ
    Aliment Pharmacol Ther; 2020 Jan; 51(1):34-52. PubMed ID: 31808566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitinase 3-like-1, Tolloid-like protein 1, and intergenic gene polymorphisms are predictors for hepatocellular carcinoma development after hepatitis C virus eradication by direct-acting antivirals.
    Mangoud NOM; Ali SA; El Kassas M; Soror SH
    IUBMB Life; 2021 Feb; 73(2):474-482. PubMed ID: 33347699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
    Hlady RA; Zhao X; El Khoury LY; Luna A; Pham K; Wu Q; Lee JH; Pyrsopoulos NT; Liu C; Robertson KD
    Hepatology; 2022 Apr; 75(4):983-996. PubMed ID: 34387871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip.
    Goto K; Roca Suarez AA; Wrensch F; Baumert TF; Lupberger J
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.